Browse

High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer

DC Field Value Language
dc.contributor.authorRhee, Jiyoung-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorCha, Yongjun-
dc.contributor.authorHam, Hye Seon-
dc.contributor.authorKim, Hwang-phill-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorPark, Jong-Wan-
dc.contributor.authorRo, Jungsil-
dc.contributor.authorLee, Keun Seok-
dc.contributor.authorPark, In Hae-
dc.contributor.authorIm, Young-Hyuck-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKim, Tae-You-
dc.date.accessioned2021-01-31T11:03:35Z-
dc.date.available2021-01-31T11:03:35Z-
dc.date.issued2011-01-
dc.identifier.citationBreast Cancer Research and Treatment, Vol.125 No.1, pp.107-114-
dc.identifier.issn0167-6806-
dc.identifier.other108438-
dc.identifier.urihttps://hdl.handle.net/10371/172993-
dc.description.abstractLapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine Patients received lapatinib 1,250 mg once daily and capecitabine 2,000 mg/m(2)/day, day 1-14, every 3 weeks. Serum samples were obtained before treatment initiation. Levels of transforming growth factor-alpha (TGF-alpha), epidermal growth factor (EGF), extracellular domains of EGFR and HER2 were measured by enzyme-linked immunosorbent assay. The effect of TGF-alpha on in vitro sensitivity of SK-BR-3 cells to lapatinib was investigated. Sixty-four patients were included. Response rate was significantly higher in patients with low serum TGF-alpha (a parts per thousand currency sign3.75 pg/ml) compared to high TGF-alpha (> 3.75 pg/ml) [61.1% (11/18) vs. 17.4% (8/46), respectively; P = 0.001]. Low serum TGF-alpha was independently associated with better response in multivariate analysis [adjusted odds ratio, 8.96; 95% confidence interval (CI) 2.4-34.2]. Time-to-progression tended to be shorter in patients with high serum TGF-alpha compared to low TGF-alpha [median 3.8 months (95% CI 2.3-5.4) vs. 6.5 (95% CI 6.1-6.8), respectively; P = 0.067]. We confirmed that TGF-alpha diminished the sensitivity of SK-BR3-cells to lapatinib in vitro. The in vitro antiproliferative effect of cetuximab in combination with lapatinib was higher than that of lapatinib alone in SK-BR3-cells exposed to TGF-alpha. These data suggest that TGF-alpha plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer.-
dc.subjectBreast cancer-
dc.subjectLapatinib-
dc.subjectTransforming growth factor-alpha-
dc.titleHigh serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1007/s10549-010-1200-9-
dc.citation.journaltitleBreast Cancer Research and Treatment-
dc.identifier.scopusid2-s2.0-78651100870-
dc.citation.endpage114-
dc.citation.number1-
dc.citation.startpage107-
dc.citation.volume125-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs10549-010-1200-9-
dc.identifier.rimsid108438-
dc.identifier.sci000284956400011-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse